H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Jasper Therapeutics today and set a price target of $20.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the thorough investigation conducted by Jasper Therapeutics, which revealed that the issues in the BEACON trial were likely due to poor patient selection rather than any problems with the briquilimab drug product. The company found no discrepancies in the drug’s manufacturing or distribution processes, and independent testing confirmed the drug’s potency and quality. Additionally, the positive results from the ETESIAN trial, which used the same drug product lot, further support the integrity of the drug.
Jasper Therapeutics is now focusing on enrolling patients with a well-documented history of CSU to avoid misdiagnosis, which has been a challenge in previous cohorts. The company plans to release new data in the first quarter of 2026, which is expected to show improved outcomes due to better patient selection. This strategic shift, along with the consistent performance of briquilimab in trials, underpins Emily Bodnar’s Buy rating for Jasper Therapeutics.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 7.9% and a 34.70% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as AnaptysBio, Olema Pharmaceuticals, and Agenus.